CVI is a spectrum of visual impairments due to brain abnormalities affecting visual processing pathways, distinct from ocular ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...

Recommendations emphasize monitoring rapid keratoconus progression in patients under 18.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF ...

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...